Navigation Links
Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
Date:8/5/2011

LAKE FOREST, Ill., Aug. 5, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of gemcitabine injection, a solution form of the drug. The solution presentations include 200 mg, 1 gm and 2 gm with a concentration of 38 mg/ml. The oncology medication had U.S. sales of more than $750 million in 2010, led by Eli Lilly's Gemzar®. Hospira expects to launch the product in early September.

Hospira is the first company to offer gemcitabine in a solution formulation for the U.S. market. The solution formulation is designed to improve pharmacist convenience and handling safety. Its concentration is the same as the reconstituted strength of the available "freeze-dried" form. The solution versions, however, eliminate the need for reconstitution, improving workflow.

"Hospira is excited to offer U.S. pharmacists a solution form of gemcitabine that reduces preparation time," said Thomas Moore, president, U.S., Hospira. "Hospira's generic gemcitabine solution gives the medical community access to a lower-cost, more convenient offering of this key oncology drug."

The approval follows the November 2010 launch of Hospira's lyophilized, or freeze-dried formulation, gemcitabine HCL for injection – the first 2 gm presentation of the product – and the July 2011 launch of the standard freeze-dried formulation in 200 mg and 1 gm presentations. With the previous launches of the freeze-dried presentations, the company will offer the generic oncology drug in a range of strengths and forms for use.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage drug delivery system and iSecure prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 --
A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Reports Second-Quarter 2011 Results
2. Hospira to Host Conference Call for Second-Quarter 2011 Results
3. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
4. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
5. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
6. Hospira Reports First-Quarter 2011 Results
7. Hospira Board Authorizes $1 Billion Share Repurchase Program
8. Hospira to Present at Bank of America / Merrill Lynch 2011 Health Care Conference May 11, 2011
9. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
10. Hospira to Host Conference Call for First-Quarter 2011 Results
11. Hospira Submits 510(k) Application to FDA for Symbiq™ Infusion System Modifications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of ... their offering. ... analyzes the worldwide markets for Dental Implants in US$ Million. The report ... Japan , Europe , ... World. Annual estimates and forecasts are provided for the ...
(Date:3/24/2017)... 24, 2017 FinancialBuzz.com News Commentary  ... According to ... cannabis market research, the legal cannabis market is projected to ... despite conflicting signals from the current presidential administration. The report ... two biggest drivers of growth in this industry are the ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... and Diagnostics, 2017 - 2035" report to their offering. ... The Deep Learning: Drug ... future outlook of the growing market of deep learning solutions within ... learning algorithms have emerged as a novel solution to generate relevant ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic ... Center for Shamanic Healing and Spiritual Awakening, proudly presents her Sacred Peru ... This sacred and spiritual journey during the Summer Solstice will also be ...
(Date:3/24/2017)... County, NY (PRWEB) , ... March 24, 2017 , ... ... Somers and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea ... a law clerk for the firm, will concentrate her practice in elder law, Medicaid ...
(Date:3/24/2017)... ... ... “Finding Christ Through Social Media: Year One #A365DayJourney to ... path toward true communion with God. “Finding Christ Through Social Media: Year One ... published author Lea Michelle Johnson, a follower of Christ, wife and mother who ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization ... could be four million Zika-related cases in the Americas within the next year. Lyme ... cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on ... Avenue, will be an educational and exciting program providing busy clinicians and allied ... chronic pain. , Oklahoma is in a healthcare crisis. The state ranks 46th ...
Breaking Medicine News(10 mins):